These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33984651)

  • 1. Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis.
    Cuculiza Henriksen A; Ammitzbøll C; Petersen ER; McWilliam O; Sellebjerg F; von Essen MR; Romme Christensen J
    Mult Scler Relat Disord; 2021 Jul; 52():102987. PubMed ID: 33984651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis.
    Mahler MR; Søndergaard HB; Buhelt S; von Essen MR; Romme Christensen J; Enevold C; Sellebjerg F
    Mult Scler Relat Disord; 2020 Oct; 45():102391. PubMed ID: 32679525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts.
    Schlüter M; Oswald E; Winklmeier S; Meinl I; Havla J; Eichhorn P; Meinl E; Kümpfel T
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34210800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
    Schneider-Hohendorf T; Schulte-Mecklenbeck A; Ostkamp P; Janoschka C; Pawlitzki M; Luessi F; Zipp F; Meuth SG; Klotz L; Wiendl H; Gross CC; Schwab N
    Mult Scler; 2021 Sep; 27(10):1491-1496. PubMed ID: 33150829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.
    Sellebjerg F; Börnsen L; Khademi M; Krakauer M; Olsson T; Frederiksen JL; Sørensen PS
    Neurology; 2009 Dec; 73(23):2003-10. PubMed ID: 19996075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.
    Kowarik MC; Astling D; Lepennetier G; Ritchie A; Hemmer B; Owens GP; Bennett JL
    Neurotherapeutics; 2021 Jan; 18(1):364-377. PubMed ID: 33258072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
    Boldrini VO; Marques AM; Quintiliano RPS; Moraes AS; Stella CRAV; Longhini ALF; Santos I; Andrade M; Ferrari B; Damasceno A; Carneiro RPD; Brandão CO; Farias AS; Santos LMB
    Front Immunol; 2022; 13():750660. PubMed ID: 35197967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis.
    Holm Hansen R; Talbot J; Højsgaard Chow H; Bredahl Hansen M; Buhelt S; Herich S; Schwab N; Hellem MNN; Nielsen JE; Sellebjerg F; von Essen MR
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35835563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.
    Nielsen BR; Ratzer R; Börnsen L; von Essen MR; Christensen JR; Sellebjerg F
    J Neuroimmunol; 2017 Sep; 310():17-25. PubMed ID: 28778440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.
    Waschbisch A; Sammet L; Schröder S; Lee DH; Barrantes-Freer A; Stadelmann C; Linker RA
    Clin Exp Immunol; 2014 Aug; 177(2):404-11. PubMed ID: 24730443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
    Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model.
    Häusler D; Nessler S; Kruse N; Brück W; Metz I
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):814-31. PubMed ID: 25641089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis.
    Canto-Gomes J; Silva CS; Rb-Silva R; Boleixa D; da Silva AM; Cheynier R; Costa P; González-Suárez I; Correia-Neves M; Cerqueira JJ; Nobrega C
    Front Immunol; 2022; 13():901165. PubMed ID: 35711452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    van Lierop ZY; Wieske L; Koel-Simmelink MJ; Chatterjee M; Dekker I; Leurs CE; Willemse EA; Moraal B; Barkhof F; Eftimov F; Uitdehaag BM; Killestein J; Teunissen CE
    Mult Scler; 2022 Jan; 28(1):102-110. PubMed ID: 33890520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.